Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SRNE    crawled date : 2021 - 08 - 02    save search
Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, "Off-the-Shelf", Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma
Published: 2021-08-02 (Crawled : 14:00) - biospace.com/
SRNE | $0.015 140K twitter stocktwits trandingview |
Health Technology
 | | O: 1.71% H: 1.8% C: -0.12%
fda phase 1 therapy trial authorized t-cell
Gainers vs Losers
87% 13%

Top 10 Gainers
MTTR | News M | $4.595 164.08% 13M twitter stocktwits trandingview |

AGBA | $2.61 108.8% 41M twitter stocktwits trandingview |
Finance
CZOO | $9.32 86.77% 18M twitter stocktwits trandingview |

EDBL | News | $6.7 78.19% 1.7M twitter stocktwits trandingview |

MTC | $2.28 46.15% 2.6M twitter stocktwits trandingview |
Technology Services
OPRT | News | $3.14 39.56% 7.6M twitter stocktwits trandingview |
Finance
VNRX | $0.8 33.33% 2.9M twitter stocktwits trandingview |
Health Technology
MLEC | $1.865 33.21% 2.4M twitter stocktwits trandingview |
n/a
PALI | $6.37 29.21% 21M twitter stocktwits trandingview |
Manufacturing
LOCL | $3.33 27.59% 43K twitter stocktwits trandingview |

Your saved searches
Save your searches and get alerts when important news are released.